Medications

Combination therapy can delay resistance of lung cancer cells

A specific genetic alteration, known as an ALK fusion, drives non-small cell lung cancer in some patients. This abnormality leads to excessive activity of the ALK protein, a key cancer promoter. These tumors can be treated ...

Oncology & Cancer

Filament formation enables cancer cells' glutamine addiction

Blocking the formation of filaments—multi-enzyme structures that fuel cancer activity—may offer new ways to control cancer cell proliferation, according to a new study led by Cornell researchers.

page 1 from 22